Compare · BOAC vs IBER
BOAC vs IBER
Side-by-side comparison of Bluescape Opportunities Acquisition Corp. (BOAC) and Ibere Pharmaceuticals (IBER): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BOAC and IBER operate in Blank Checks (Finance), so they compete in similar markets.
- BOAC is the larger of the two at $743.4M, about 4.4x IBER ($167.2M).
Bluescape Opportunities Acquisition Corp.
Bluescape Opportunities Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Dallas, Texas.
Ibere Pharmaceuticals
Ibere Pharmaceuticals focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in Philadelphia, Pennsylvania.
Latest BOAC
- SEC Form SC 13G/A filed by Bluescape Opportunities Acquisition Corp. (Amendment)
- Bluescape Opportunities Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 25-NSE filed by Bluescape Opportunities Acquisition Corp.
- Bluescape Opportunities Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Bluescape Opportunities Acquisition Corp. Will Redeem its Public Shares and Will Not Consummate an Initial Business Combination
- SEC Form 10-Q filed by Bluescape Opportunities Acquisition Corp.
- SEC Form 10-Q/A filed by Bluescape Opportunities Acquisition Corp. (Amendment)
- SEC Form 10-K/A filed by Bluescape Opportunities Acquisition Corp. (Amendment)
- SEC Form 10-Q filed by Bluescape Opportunities Acquisition Corp.
- SEC Form 10-K filed by Bluescape Opportunities Acquisition Corp.
Latest IBER
- SEC Form 15-12G filed by Ibere Pharmaceuticals
- SEC Form 25-NSE filed by Ibere Pharmaceuticals
- Ibere Pharmaceuticals filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Ibere Pharmaceuticals Will Redeem All Outstanding Ordinary Shares Included In Units Issued In IPO Effective As Of Close Of Business On March 2; Per-Share Redemption Price For Public Shares Will Be ~$10.17; Expects That NYSE Will File Form 25 To Delist Co
- SEC Form SC 13G filed by Ibere Pharmaceuticals
- SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
- SEC Form SC 13G filed by Ibere Pharmaceuticals
- SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
- SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
- SEC Form 10-Q filed by Ibere Pharmaceuticals